SELECTA BIOSCI(SELB) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Recent Pipeline Progress and Anticipated Milestones • Enrollment On Track in the Phase 3 AURORA Trial of Descartes-08 in Participants with MG. The randomized, double- blind, placebo-controlled Phase 3 AURORA trial is designed to assess Descartes-08, Cartesian's autologous anti-B cell maturation antigen (BCMA) chimeric a ...